A photo of Maureen O'Brien.

Medical Director, Leukemia/Lymphoma Program

Associate Professor, UC Department of Pediatrics

513-803-1678

513-636-3549

Board Certified

My Biography & Research

Clinical Interests

Leukemia; lymphoma

Research Interests

Molecular etiology of pediatric leukemias, especially in children with Down syndrome; novel therapeutics for relapsed and high-risk leukemia and lymphoma

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Departments

Cancer and Blood Diseases, Leukemia, Oncology, Cancer and Blood Diseases

Cincinnati Children's Blog

Living Life to the Fullest

BlogCancer and Blood Diseases

Living Life to the Fullest: 9 Years After Chronic Myeloid Leukemia Diagnosis

By Nancy Young4/1/2019

My Locations

My Education

MD: Harvard Medical School, Boston, MA, 2000.

Residency: Boston Combined Residency Program, Boston Children's Hospital and Boston Medical Center, Boston, MA, 2003.

Fellowship: Stanford University School of Medicine, Stanford, CA, 2007.

MS: Stanford University, Stanford, CA, 2008.

Certification: Pediatrics, 2003; Pediatric Hematology/Oncology, 2009.

My Publications

Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Horton, TM; Whitlock, JA; Lu, X; O'Brien, MM; Borowitz, MJ; Devidas, M; Raetz, EA; Brown, PA; Carroll, WL; Hunger, SP. British Journal of Haematology. 2019; 186:274-285.

Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis. Young, J; Sawyer, J; Jenkins, M; O'Brien, M; Luchtman-Jones, L; Breese, EH. Pediatric Blood and Cancer. 2019; 66:e27719-e27719.

Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study. Sopfe, J; Endres, A; Campbell, K; Hayes, K; Trout, AT; Liang, X; Lorsbach, R; O'Brien, MM; Cost, CR. Pediatric Blood and Cancer. 2019; 66:e27613-e27613.

Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. Ramsey, LB; Mizuno, T; Vinks, AA; O'Brien, MM. Pediatric Blood and Cancer. 2019; 66:e27618-e27618.

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Bhojwani, D; Sposto, R; Shah, NN; Rodriguez, V; Yuan, C; Stetler-Stevenson, M; O'Brien, MM; McNeer, JL; Quereshi, A; Cabannes, A; et al. Leukemia. 2019; 33:884-892.

Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia. Mizuno, T; O'Brien, MM; Vinks, AA. European Journal of Pharmaceutical Sciences. 2019; 128:209-214.

Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis. Gurunathan, A; Boucher, AA; Mark, M; Prus, KM; O'Brien, MM; Breese, EH; Mizukawa, BE; Absalon, MJ; Nelson, AS; Jordan, MB; et al. Pediatric Blood and Cancer. 2018; 65:e27400-e27400.

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Gore, L; Locatelli, F; Zugmaier, G; Handgretinger, R; O'Brien, MM; Bader, P; Bhojwani, D; Schlegel, P; Tuglus, CA; von Stackelberg, A. Blood Cancer Journal. 2018; 8.

Cost-Effectiveness Analysis of an Adherence-Promotion Intervention for Children With Leukemia: A Markov Model-Based Simulation. McGrady, ME; Eckman, MH; O'Brien, MM; Pai, AL H. Journal of Pediatric Psychology. 2018; 43:758-768.

Radiation dose reduction through combining positron emission tomography/computed tomography (PET/CT) and diagnostic CT in children and young adults with lymphoma. Qi, Z; Gates, EL; O'Brien, MM; Trout, AT. Pediatric Radiology: roentgenology, nuclear medicine, ultrasonics, CT, MRI. 2018; 48:196-203.